Association of the GSTP1 and NQO1 Polymorphisms and Head and Neck Squamous Cell Carcinoma Risk by Cho, Chang Gun et al.
Chang Gun Cho, Seok Ki Lee*,
Soon-Yhul Nam
� , Moo-Song Lee
� ,
Sang-Wook Lee
�, Eun Kyung Choi
�, 
Heon Joo Park
‖, Sang Yoon Kim
�
Department of Otorhinolaryngology-Head and Neck
Surgery, Dongguk University International Hospital,
Goyang; Depatment of Otolaryngology*, Kangwon
National University Hospital, Chunchon; Department of
Otolaryngology
� , Department of Preventive Medicine
�
and Department of Radiation Oncology
�, University of
Ulsan College of Medicine, Asan Medical Center,
Seoul; Department of Microbiology
‖, College of
Medicine, Inha University Hospital, Incheon, Korea
Address for correspondence
Sang Yoon Kim, M.D.
Department of Otolaryngology, University of Ulsan
College of Medicine, Asan Medical Center, 388-1
Poongnap-dong, Songpa-gu, Seoul 138-736, Korea 
Tel : +82.2-3010-3710, Fax : +82.2-489-2773
E-mail : sykim2@amc.seoul.kr
*This study was supported by a grant from the National
R&D Program for the Cancer Control Program (Grant
No. 0320320-2), Ministry of Health & Welfare, Republic
of Korea.
1075
J Korean Med Sci 2006; 21: 1075-9
ISSN 1011-8934
Copyright � The Korean Academy
of Medical Sciences
Association of the GSTP1 and NQO1 Polymorphisms and Head and
Neck Squamous Cell Carcinoma Risk 
Received : 13 February 2006
Accepted : 24 April 2006
The GSTP1 and NQO1 have been reported to be associated with an increased risk
for smoking related head and neck squamous cell carcinoma (HNSCC). The pur-
pose of this study was to determine the effect of these metabolic gene polymorphisms
on the risk of HNSCC. The study population included 294 histologically confirmed
HNSCC cases and 333 controls without cancer. Genotyping analysis of the GSTP1
Ile105Val and NQO1 Trp139Arg genes was performed by polymerase chain reac-
tion-based techniques on DNA prepared from peripheral blood. The Mantel-Haen-
szel 
2 test was used for statistical analysis. The allele frequencies of the GSTP1
and NQO1 polymorphisms were not statistically significant between cases and con-
trols. In analyzing the association between smoking amounts and genetic polymor-
phisms, GSTP1 and NQO1 polymorphisms were associated with cigarette smoking
amounts in cases. G allele containing genotypes in GSTP1 and T allele containing
genotypes in NQO1 were associated with a tobacco dose-dependent increase in
risk of HNSCC and these genotype distributions were statistically significant (p<
0.05). We found that the GSTP1 105Val allele and NQO1 139Arg allele were asso-
ciated with tobacco dose-dependent increase in risk of HNSCC. GSTP1 and NQO1
genotype polymorphisms may play an important role in the development of smok-
ing related HNSCC. 
Key Words : Glutathione S-Transferase pi; NADH dehydrogenase (quinone); Head and Neck Neoplasms;
Carcinoma, Squamous Cell; Smoking 
INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) which
includes cancers of the larynx, pharynx, and oral cavity, show
a wide range of geographical variations in incidence. Although
tobacco and alcohol consumption are recognized as the major
causes of HNSCC, geographic distribution of cancer incidence
is not strongly correlated with areas of high tobacco and alco-
hol consumption. Also, only a small number of smokers actu-
ally develop HNSCC (1). This suggests a gene-environmen-
tal interaction where host components, likely genetics, have
an influential role in the susceptibility to HNSCC (2). The
presence of polymorphisms in genes coding for enzymes in-
volved in tobacco-related carcinogen metabolism, such as the
glutathione S-transferase (GST) and NAD(P)H:quinone oxi-
doreductase (NQO) enzymes, could explain this difference
in susceptibility. It has recently been suggested that these
inherited differences, in the capacity to metabolize such che-
micals, are the modifiers of individual susceptibility to envi-
ronmentally induced HNSCC (3). 
Human GST enzymes can be subdivided into five main
classes, alpha (A), mu (M), pi (P), theta (T), and zeta (Z). Each
class includes one or more isoenzymes with different, but some-
times overlapping, substrate specificity (4, 5). As a result of
conjugation with glutathione, the potential carcinogens are
eliminated and DNA, or other important biomolecules, are
protected against damage or adduct formation. The GSTP1
gene encodes for the isoenzyme GSTP1-1. GSTP1-1 is a major
enzyme in the detoxification of tobacco-related metabolic
products and, quantitatively, the most abundant GST enzyme
in the human head and neck area (6). The GSTP1-1 enzyme
level has been extensively studied in relation to tobacco-relat-
ed malignancies. Elevated tissue levels of GSTP1-1 enzyme
have been found in stomach, colorectal, bladder, oral, phar-
ynx, larynx, lung, skin, and breast tumors compared with
normal tissues of matched controls (7). Ali-Osman et al. have
described a polymorphism of GSTP1, resulting from a sin-
gle base change at codon 105, that produces an enzyme with
reduced capacity for detoxifying a number of carcinogens (8).
Recently, there have been several reports describing a higher1076 C.G. Cho, S.K. Lee, S.-Y. Nam, et al.
risk of developing HNSCC at pharyngeal locations in patients
who are Val homozygous for the GSTP1 Ile105Val variant (9).
NQO1 is also a detoxification enzyme that plays a critical
role in protecting cells against chemically induced oxidative
stress, cytotoxicity, mutagenicity, and carcinogenicity (10).
NQO1 protects cells from oxidative damage by preventing
the generation of reactive oxygen species through the reduc-
tion of endogenous quinines, and by reducing certain envi-
ronmental carcinogens, such as nitroaromatic compounds,
heterocyclic amines, and possibly cigarette smoke condensate.
Furthermore, NQO1 reduces the formation of DNA adducts
induced by benzo[a]pyrene 3,6-quinone, one of the impor-
tant carcinogenic polycyclic aromatic hydrocarbons identi-
fied in cigarette smoke (11). However, under specific circum-
stances, metabolism by NQO1 yields more active products
that can actually produce reactive oxygen species or undergo
rearrangement to generate alkylating species (12). Therefore,
NQO1 exerts both beneficial and harmful effects, which vary
depending on the substrate. Many epidemiological studies
have been performed to examine NQO1 polymorphism in
tobacco-related cancers. These have shown that the NQO1
variant allele can modify the risk of colorectal cancer, lung can-
cer, renal cell carcinoma, and basal cell carcinoma (13-16).
In the present study, we investigated GSTP1 and NQO1
polymorphisms, in a large series of Korean patients with HN-
SCC and in matched controls, to determine the association
between genetic polymorphisms and HNSCC risk. We also
assessed the association between the tobacco exposure of all
patients and GSTP1 and NQO1 polymorphisms.
MATERIALS AND METHODS
Study subjects
The study population consisted of 294 HNSCC cases and
333 cancer-free controls, recruited from the Department of
Otolaryngology, at Asan Medical Center, from April 1994
to January 2004. All study participants were Korean. The
case group consisted of 267 male patients (90.8%) and 27
female patients (9.2%); 251 cases were smokers with a mean
age of 62 yr, and 43 were non-smokers with a mean age of
57 yr. Pathology reports were used to confirm the diagnosis
of HNSCC for all cases. The control group consisted of 277
male patients (83.2%) and 56 female patients (16.8%); 312
were smokers with a mean age of 51 yr, and 21 were non-
smokers with a mean age of 42 yr (Table 1). Controls were
randomly selected from inpatients and outpatients with no
history of cancer and were diagnosed with benign head and
neck lesions. The distribution of primary cancer sites, among
cases, is shown in Table 1.
For study purposes, subjects were divided into non-smok-
ers and ever-smokers. Ever-smokers were defined as anyone
who had smoked at least one pack-year; a pack-year was de-
fined as the product of [{number of cigarettes consumed per
day}×{duration of smoking (years)}]. Ever smokers were
grouped as mild (≤30 pack-years) and heavy (>30 pack-
years) smokers. Non-smokers were defined as individuals
who had smoked less than one pack-year. Informed consent
was obtained from all study subjects prior to participation.
Genotyping methods
After informed consent was obtained, each subject donat-
ed ten milliliters of blood. A B lymphocyte pellet, obtained
from the buffy coat by centrifuging the whole blood, was used
for DNA extraction using a DNA purification kit (GEN-
TRA, Minneapolis, MN, U.S.A.). SNP genotyping was per-
formed by SNP-ITTM assays using the SNPstream 25KTM
System (Orchid Biosciences, NJ, U.S.A.). The genomic DNA
region spanning the polymorphic site was PCR amplified
using one phosphothiolated primer and one regular PCR pri-
mer (Table 2). The amplified PCR products were digested
with exonuclease. The 5′ phosphothiolates protected one
strand of the PCR product from exonuclease digestion, result-
ing in the generation of a single-stranded PCR template. The
single-stranded PCR template was then overlaid onto a 384
well plate that contained covalently attached SNP-ITTM pri-
mer extension, designed to hybridize immediately adjacent












Age (yr) 62.0 (34-83) 56.9 (30-82) 50.7 (30-77) 42.4 (30-55)
Sex
Male 245 (97.6%) 22 (51.2%) 273 (87.5%) 4 (19.0%)
Female 6 (2.4%) 21 (48.8%) 39 (12.5%) 17 (81.0%)
Alcohol status
Drinkers 213 (84.9%) 29 (67.4%) 197 (63.1%) 6 (28.6%)
Non-drinkers 38 (15.1%) 14 (32.6%) 115 (36.9%) 15 (71.4%)
Site
Larynx  146 (58.2%) 9 (20.9%)
Oral cavity 34 (13.5%) 23 (53.5%)
Oropharynx 34 (13.5%) 6 (14.0%)
Hypopharynx 37 (14.8%) 5 (11.6%)
Table 1. Frequency distribution analysis of demographic and
risk factors
Gene-SNP Primer Sequence (5′ -3′ )
Table 2. Primers for amplification and sequencing of genes
GSTP1 PCR Forward  TGGTGGACATGGTGAATG
Ile105Val PCR Reverse  AACCCTGGTGCAGATGCT
Genotyping CGTGGAGGACCTCCGCTGCAAATAC
NQO1  PCR Forward  ATTCTGAAAGGCTGGTTTGAG
Trp139Arg PCR Reverse  CCAGAAGCTGGCTGTCAG
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formed with the SNaPshot ddNTP Primer Extension Kit
(Applied Biosystems, Foster City, CA, U.S.A.). To purify the
product of the primer extension reaction, one unit of SAP
(shrimp alkaline phosphatase) was added to the reaction mix-
ture and was incubated at 37℃ for one hour, followed by
fifteen minutes at 72℃ for enzyme inactivation. The DNA
samples, containing the extension products and Genescan
120 Liz size standard solution, were added to Hi-Di forma-
mide (Applied Biosystems). The mixture was incubated at
95℃ for five minutes, then placed on ice for another five
minutes. It was then analyzed by electrophoresis in an ABI
Prism 3700 Genetic analyzer. The results were analyzed using
GeneScan and Genotyper software (Applied Biosystems).
Statistical analysis
The distributions of the GSTP1 and NQO1 genotypes
between patients and controls were compared using the Man-
tel-Haenszel  2 test. The frequencies of genotypes were ana-
lyzed between the cases and the controls within three sub-
groups of wild type, heterozygote, and homozygote mutant.
Throughout this study, a p-value of <0.05 was considered sta-
tistically significant. Mantel-Haenszel  2 test was also used
to evaluate the association between the GSTP1 and NQO1
genotypes and smoking status in HNSCC risk. The associa-
tion between genotypes and smoking status was evaluated
within subgroups of the GSTP1 and NQO1 genotypes, the
wild type group and the combined heterozygote/homozygote
mutant group.
RESULTS
Table 3 shows the GSTP1 and NQO1 genotype distribu-
tions among cases and controls. The distribution of the GS-
TP1 and NQO1 genotypes among controls were in agree-
ment with the Hardy-Weinberg equilibrium. The frequen-
cies of GSTP1 and NQO1 genotypes in controls were simi-
lar to those previously observed in Koreans (17). When com-
paring the genotype distribution between control individu-
als and HNSCC patients, we observed that the frequency of
the wild type GSTP1 and NQO1 genotype was slightly ele-
vated in HNSCC patients, but the difference was not statis-
tically significant (Table 3).
GSTP1 and NQO1 polymorphisms were associated with
cigarette smoking and the risk of HNSCC in the case group
(p<0.05). The frequency of genotype AA in GSTP1 Ile105Val
was 83.7% in non-smokers, 70.1% in mild smokers, and
66.7% in heavy smokers; the frequency of the G allele conta-
ining genotypes (genotypes GA and GG) was 16.3%, 29.9%,
and 33.3%, respectively. Genotype distributions were statisti-
cally significant (p=0.0114), and we observed that the GSTP1
105Val allele was associated with a tobacco dose-dependent
increase in risk of HNSCC (Table 4). The frequency of geno-
type CC in NQO1 Trp139Arg was 100% in non-smokers,
98.7% in mild smokers, and 94.8% in heavy smokers, and
the frequency of T allele containing genotypes (genotype TC
and TT) was 0%, 1.3%, and 5.2%, respectively (Table 5). The
NQO1 139Arg allele was associated with a tobacco dose-de-
pendent increase in risk of HNSCC and these genotype distri-
butions were statistically significant (p=0.0454). In the con-
trol groups, no significant difference of genotype distribution
was found between wild type and mutant genotypes (Table
4, 5). 
DISCUSSION
In this hospital-based, case-control study of 627 Korean
patients, polymorphisms in two of the genes involved with
metabolism of tobacco-induced carcinogens, GSTP1 Ile105Val
and NQO1 Trp139Arg, were examined for association with
0 PY 1-29 PY >30 PY p-value
Cases
AA 36 (83.7%) 54 (70.1%) 110 (66.7%) 0.0114
GA+GG  7 (16.3%) 23 (29.9%) 55 (33.3%)
Controls
AA 11 (52.4%) 109 (63.0%) 91 (65.5%) 0.5737
GA+GG 10 (47.6%) 64 (37.0%) 48 (34.5%)
PY, pack year.
0 PY 1-29 PY >30 PY p-value
Cases
CC 43 (100%) 76 (98.7%) 163 (94.8%) 0.0454
CT+TT 0 (0%) 1 (1.3%) 9 (5.2%)
Controls
CC 19 (90.5%) 164 (96.5%) 126 (92.6%) 0.3946







Table 3. Genotype distribution of GST1 and NQO1 polymorphi-
sms in squamous cell carcinoma patients and controls
Table 4. Association between GSTP1 Ile105Val genotypes and
smoking amounts
Table 5. Association between NQO1 Trp139Arg genotypes and
smoking amounts
GSTP1 Ile105Val
AA 201 (68.6) 211 (63.4) 
GA 85 (29.0) 112 (33.6)
GG 7 (2.4) 10 (3.0)
NQO1 Trp139Arg
CC 283 (96.6) 309 (94.5)
CT 10 (3.4) 17 (5.2)
TT 0 (0) 1 (0.3)1078 C.G. Cho, S.K. Lee, S.-Y. Nam, et al.
HNSCC risk. We found no significant difference among the
genotype distribution of polymorphic GSTP1 and NQO1
genes between HNSCC cases and controls. Although there
are a large number of reports which suggest that polymor-
phisms of GSTP1 and NQO1 genes influence the suscepti-
bility to cancer, the results of this present study suggest that
the polymorphisms of the genes alone have only minor im-
portance in the susceptibility to HNSCC. However, this find-
ing is likely not due to the lack of a relationship between ge-
netic polymorphisms and risk of HNSCC, but rather because
biomolecular studies for genetic polymorphisms are still in
the early phases of development.
To date, the role of several different DNA polymorphisms
in detoxification genes have been examined in numerous case-
control HNSCC studies. Results have often been conflicting,
and some report weak-to-moderate associations, while others
show no elevation of risk. These conflicting results may be
due to relatively small samples sizes, or the lack of proper
controls for other environmental exposures that are also risk
factors for HNSCC. This study is also limited by the relatively
small number of cases and controls. And the control popu-
lation in this study was a convenience sample, and cases and
controls were not balanced for confounding factors, age and
sex. Therefore further studies with a larger number of subjects
and well controlled risk factors such as age, sex, smoking, and
alcohol exposures are needed.
In addition, the concept of genetic susceptibility is extre-
mely complex and involves multiple cellular systems regu-
lated by hundreds of genes (18), therefore, it is difficult to
explain the association between genetic polymorphisms and
risk of HNSCC by analyzing only one or two genes. In con-
clusion, a variety of analysis is needed, including a combined
analysis of multiple polymorphic genotypes in detoxification
enzymes, and of haplotypes to multiple enzymes associated
with metabolisms of tobacco-induced carcinogens. 
In our analysis, GSTP1 and NQO1 polymorphisms were
associated with the status of  cigarette smoking and, there-
fore an increased risk of HNSCC in the case group (p<0.05).
For evaluation of smoking and genetic polymorphisms, we
divide the subjects into three subgroups: non-smokers, mild
smokers, and heavy smokers. Frequencies of the wild type
GSTP1 and NQO1 genotypes were high in all three sub-
groups compared to frequencies of the mutant allele contain-
ing genotypes. Both GSTP1 and NQO1 genotype distribu-
tions in all three subgroups of the cases were statistically sig-
nificant, and the GSTP1 105Val allele and NQO1 139Arg
allele were associated with a tobacco dose-dependent increase
in risk of HNSCC. It is likely that because GSTP1 and NQO1
are involved in the metabolism of specific tobacco smoke
intermediates, ever smokers with the variant alleles, which
are associated with reduced enzymatic activities, experience
deleterious effects from reduced carcinogen detoxification.
Therefore, there is a greater impact on HNSCC risk in smokers
based on pack-years of smoking. This suggests that a predis-
position to genetic factors, such as GSTP1 and NQO1 vari-
ants, plays a role in the development of HNSCC in smokers.
However, there were no significant differences in the distri-
bution of genetic variants among the smoking status in con-
trols. There was also no significant difference in the genotype
distribution of polymorphic GSTP1 and NQO1 genes bet-
ween HNSCC cases and controls. From this point of view,
environmental effects such as cigarette smoking are likely to
dominate over genetic effects.
Several studies have examined the relationship between
the GSTP1 polymorphisms and smoking status in HNSCC,
and the results are not consistent. Ophuis et al. (19) found
that HNSCC patients with the GSTP1 G allele containing
genotypes (GA and GG) showed increased odds ratios for
smoking compared with the wild type GSTP1 genotype.
However, McWilliams et al. (20) found no association between
the GSTP1 genotypes and smoking status in HNSCC risk.
There are no studies performed to determine the relationship
between the NQO1 polymorphisms and smoking in HNSCC.
However, in bladder cancer, which is similar to HNSCC epi-
demiology in that it is strongly related to tobacco exposure,
there are several studies that suggest the association between
NQO1 genetic polymorphisms and the development of smok-
ing related bladder cancer (21, 22).
Assessment of smoking or alcohol consumption is difficult,
especially for the total accumulative exposure. Exposure usu-
ally takes place over many years and is not always consistent.
In addition, different cigarette brands may yield completely
different nicotine and tar exposures. Therefore, development
of biomarkers, that could indicate the level of exposure and
the period of consumption, would be more helpful.
In summary, to study the effect of different genotypes on
the risk of developing HNSCC, we conducted a case-control
study of two genetic polymorphisms in HNSCC. We were
unable to demonstrate a significant association between gene-
tic polymorphisms and risk of HNSCC. However, in analy-
sis of the association between smoking and genetic polymor-
phisms, GSTP1 105Val allele and NQO1 139Arg allele were
associated with tobacco dose-dependent increase in risk of
HNSCC in the case group. Our findings suggest that the
GSTP1 and NQO1 genotype polymorphisms may play an
important role in the development of HNSCC, and that the
association between cigarette smoking and HNSCC may be
modulated by these genetic polymorphisms.
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